Emerging drugs in the treatment of advanced gastric cancer

Expert Opinion on Emerging Drugs

Volumn 13, Issue 1, 2008, Pages 135-144

  Tetzlaff, Eric D ^a   Cen, Putao ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biotherapy; Chemotherapy; Gastric neoplasm; Gastroesophageal neoplasm

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; TEGAFUR; URACIL;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; STOMACH CANCER; STOMACH PERFORATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; STOMACH NEOPLASMS;

EID: 41449089109     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.1.135     Document Type: Review

References (49)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
2. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best practice and research clinical. Gastroenterology 2006;20:633-49 • Review article of risk factors for gastric cancer.
3. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared to surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
5. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8
6. Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:58-91
7. Murad A, Santiago F, Petroianu A. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41
8. Scheithauer W, Kornek G, Zeh B. In Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial, eds 1995. 68. Second International Conference on Biology, Prevention and Treatment of GI Malignancy, Koln, Germany (Abstract)
9. Ries LAG, Eisner MP, Kosary CL, et al. (eds). SEER cancer statistics review, 1975 - 2002. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site; 2005
10. Cunningham D, Rao S, Starling N, et al. Randomized multicenter Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric cancer. The REAL 2 trial. Proc Am Soc Clin Oncol 2006;24:18S (Abstract no. 4017) •• One of the largest trials in advanced gastroesophageal cancer. It establishes the role of oxaliplatin and capecitabine in advanced disease.
11. Van Cutson E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the v325 study group. J Clin Oncol 2006;24:4991-7 •• This was the pivotal trial that lead to the approval by the FDA for the use of docetaxel for the treatment of advanced gastroesophageal cancer.
12. Dank M, Zaluski J, Barone C, et al. Randomized phase 3 trial of irinotecan (CPT-11) 5FU/folinic acid (FA) versus CDDP + 5FU in 1st-line advanced gastric cancer patients. Proc Am Soc Clin Oncol 2005;23:15S (Abstract No. 4003)
13. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter Phase II study of irinotecan, cisplatin, and Bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-6 • One of the first completed trials of biotherapy in advanced gastroesophageal cancer.
14. Vanhoefer U, Rougier P, Wilke H. Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57
15. Webb A, Cunningham D, Scarffe JH. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7 • This trial established ECF as an option for the first line treatment of advanced gastroesophageal cancer.
16. Ohtsu A, Shimada Y, Shirao K. Randomized Phase III trial of fluorouracil versus flourouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol 2003;21:54-9
17. Wils JA, Klein HO, Wagener DJ. FAMTX: A step ahead in the treatment of advanced gastric cancer: An EORTC study. J Clin Oncol 1991;9:827-31
18. Ross P, Nicolson M, Cunningham D. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004
19. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000;18:4001-3
20. Kang Y, Kang WK, Shin DB, et al. Randomized Phase III trial of capecitabine/cisplatin (XP) versus continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer: efficacy and safety results. Proc Am Soc Clin Oncol 2006;24:18S (Abstract no. LBA 4018)
21. Ajani JA, Fodor MB, Tjulandin SA, et al. A multi-institutional Phase II randomized trial of docetaxel plus cisplatin (DC) or DC plus 5-fluorouracil (DCF) in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660-7
22. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3210-6 • Results from this study further describe the quality of life benefits of docetaxel in advanced gastroesophageal cancer.
23. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a Phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007;25:3205-9
24. Al-Batran S, Hartman J, Probst S, et al. A randomized Phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FLO) versus fluorouracil, leucovorin, and cisplatin (FLP). 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006;24:18S (Abstract LBA4016)
25. Shirasaka T, Shimamato Y, Ohsimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;(5):548-57
26. Shirasaka T, Shimamato, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53(17):4004-9
27. Sakata Y, Ohtsu A, Horikoshi N, et al. Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;(11):1715-20
28. Chollet P, Schoffski P, Weigang-Kohler K, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003;(9):1264-70
29. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58(3):191-7
30. Boku N, Yamamoto S, Shirao K, et al. Randomized Phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer. 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S)(Suppl):(Abstract LBA4513)
31. Narahara H, Koizumi W, Hara T, et al. Randomized Phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin versus S-1 in RCT in the treatment for stomach cancer. 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S)(Suppl):(Abstract 4514)
32. Tetzlaff ED, Faust J, Ajani JA. Long-term survival of a western patient with metastatic gastric cancer treated with S-1 plus cisplatin. Gastric Cancer 2006;9:140-3
33. Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with metastatic gastric carcinoma. J Clin Oncol 2005;23(28):1-9
34. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2004;89:2207-12
35. Ajani JA, Lee FC, Singh DA, et al. Multicenter Phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:663-7
36. Futatsuki K, Wakui A, Nakao I, et al. Late Phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994;21:1033-8
37. Li-Shin L, Hecht J. A Phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc Am Soc Clin Oncol 2000;19:289a (Abstract 1130)
38. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a Phase II study. Cancer 2002;94:641-6
39. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23
40. Blanke CD, Haller DG, Benson AB, et al. A Phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 2001;12:1575-80
41. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
42. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-12
43. Jhawer M, Kelsen D, Shah M. Incorporating biologic therapies in the management of gastroesophageal cancers. Gastrointest Cancer Res 2007;1(Suppl 1):S22-9 • Review of the pathways involved in progression of gastroesophageal cancer and potential targeted agents.
44. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):S9-15
45. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
46. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Annals of Oncol 2007;18:510-7 • The first completed manuscript in advanced gastroesophageal cancer using an EGFR inhibitor.
47. Food and Drug Administration. Available at: www.fda.gov. Accessed on 9/18/2007
48. Tetzlaff ED, Correa AM, Baker J, et al. Impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. Cancer 2007;109:1989-95
49. Ajani JA, Phan A, Ho L, et al. Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S)(Suppl):4612